Journal article · 2022 · Open access
Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions
Frontiers in Pharmacology, 13, 1031992 · Published 17 October 2022 · DOI 10.3389/fphar.2022.1031992
In brief
“Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions” is a 2022 journal article by David F Cella and 7 co-authors, published in Frontiers in Pharmacology. OpenAlex counts 20 citations as of 22 November 2026, which puts it in the top 8% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Pharmacology.
- Citations
- 20
- Most cited in
- 2026 (7)
- Field-weighted impact
- 2.05
- References
- 19
- Authors
- 8
Abstract
Introduction: Regulatory agencies encourage the incorporation of the patient voices throughout clinical drug development. Patient-Reported Outcomes (PROs) offer one way of doing this and their use has markedly increased in many therapeutic areas, particularly oncology, in recent years. However, few oncology drug labels include PRO data and those which do, offer little consistency. Objective: To provide multidisciplinary perspectives (patient, pharmaceutical industry, PRO researcher, regulatory expert) on PRO data in oncology drug labels. Methods: PRO data in the labels of drugs approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for oncology indications between 2010 and 2020 were critically reviewed by authors who provided their insights on the advantages and disadvantages/gaps. Results: Forty-six oncology drugs included PRO data in their labels. Differences were observed between FDA and EMA PRO labeling (e.g., PRO concept, use of tables and graphs to display PROs or reference to clinical meaningfulness). In providing their perspectives on the number and nature of PROs in labels, authors noted limitations including: the low proportion of oncology drugs with PRO labeling, limited PRO information in labels, lack of patient-friendly language, and potential bias towards positive outcomes. Lack of consistency within- and between-agencies was noted. Conclusion: Despite regulatory agencies’ commitment to incorporate patient voices in regulatory decisions, availability of PRO information is limited in oncology drug labels. While several PRO guidance documents are available from regulatory and Health Technology Assessment agencies, harmonization of PRO guidance for labeling inclusion around the world is needed to better inform prescribers and consequently their patients in the process of shared medical decisions.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cella, D. F., Chen, C.-I., Quek, R. G., Uribarren, A., Reaney, M. D., Mastey, V., Collyar, D. E., & Chassany, O. (2022). Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions. Frontiers in Pharmacology, 13, 1031992. https://doi.org/10.3389/fphar.2022.1031992
MLA 9
Cella, David F, et al. “Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.” Frontiers in Pharmacology, vol. 13, 2022, p. 1031992. https://doi.org/10.3389/fphar.2022.1031992.
Chicago
Cella, David F, Chieh-I Chen, Ruben G.W. Quek, Ainhoa Uribarren, Matthew D. Reaney, Vera Mastey, Deborah E. Collyar, and Olivier Chassany. 2022. “Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.” Frontiers in Pharmacology 13: 1031992. https://doi.org/10.3389/fphar.2022.1031992.
Harvard
Cella, D. F. et al. (2022) ‘Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions’, Frontiers in Pharmacology, 13, p. 1031992. doi:10.3389/fphar.2022.1031992.
IEEE
D. F. Cella et al., “Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions,” Frontiers in Pharmacology, vol. 13, p. 1031992, 2022, doi: 10.3389/fphar.2022.1031992.
BibTeX
@article{cella2022patient,
title = {{Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions}},
author = {Cella, David F and Chen, Chieh-I and Quek, Ruben G.W. and Uribarren, Ainhoa and Reaney, Matthew D. and Mastey, Vera and Collyar, Deborah E. and Chassany, Olivier},
journal = {Frontiers in Pharmacology},
year = {2022},
volume = {13},
pages = {1031992},
doi = {10.3389/fphar.2022.1031992},
url = {https://doi.org/10.3389/fphar.2022.1031992}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 2 | |
| 2024 | 6 | |
| 2025 | 5 | |
| 2026 | 7 |
Its field-weighted citation impact is 2.05: it has been cited 2.05 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcomes
- drug labeling
- oncology drugs
- FDA
- EMA
- regulatory guidelines
- patient involvement in drug development
- shared decision-making
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Cella, D. F., Chen, C.-I., Quek, R. G., Uribarren, A., Reaney, M. D., Mastey, V., Collyar, D. E., & Chassany, O. (2022). Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions. Frontiers in Pharmacology, 13, 1031992. https://doi.org/10.3389/fphar.2022.1031992
How many times has this paper been cited?
20 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Pharmacology: sign in and open the full text from this page.
Who wrote this paper?
David F Cella, Chieh-I Chen, Ruben G.W. Quek, Ainhoa Uribarren, Matthew D. Reaney, Vera Mastey, Deborah E. Collyar, Olivier Chassany.
What is the DOI of this paper?
10.3389/fphar.2022.1031992, permanently at https://doi.org/10.3389/fphar.2022.1031992. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.